查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1493374

自體免疫溶血性貧血治療市場規模、佔有率和趨勢分析報告：按類型、藥物類別、給藥途徑、分銷管道、地區和細分市場趨勢：2024-2030

Autoimmune Hemolytic Anemia Treatment Market Size, Share & Trends Analysis Report By Type, By Drug Class (Corticosteroids, Immunosuppressive Agents), By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

自體免疫溶血性貧血治療市場的成長與趨勢：

Grand View Research, Inc.最新報告顯示，2030年全球自體免疫溶血性貧血治療市場預計將達到11.6億美元，2024年至2030年複合年成長率為6.5%。

全球自體免疫免疫性溶血性貧血 (AIHA) 病例數量不斷增加、新治療藥物的推出、研發活動的活性化以及積極主動的政府舉措是推動成長的關鍵因素。例如，法國和丹麥的 AIHA 發生率估計分別為每 10 萬人 2.4 例和 17.0 例。

治療 AIHA開發新藥的研發勢頭強勁，預計將成為市場擴張的驅動力。製藥公司和研究機構正在積極致力於開發新的有效治療方法來管理 AIHA。例如，Zenas BioPharma 正在開發用於溫性自體免疫溶血性貧血 (wAIHA) 患者的 obexelimab。該藥物正在進行 3 期臨床試驗，評估其對 wAIHA 患者的療效和安全性。同樣，諾華正在進行一項臨床試驗，以評估 ianalumab (VAY736) 對於至少一種熱自體免疫溶血性貧血治療失敗的患者的安全性和有效性。

此外，由於政府機構的更多參與以及監管機構為改善罕見疾病管理的醫療服務而採取的有利舉措，預計未來幾年將推出有效的治療解決方案。例如，2019年12月，美國FDA授予nipocalimab治療wAIHA的孤兒藥資格，2019年7月，美國FDA授予nipocalimab用於同一適應症的簡審類。候選化合物的這一特殊指定預計將加快臨床試驗和核准過程。

主要參與者正在採取各種市場策略，例如收購和新產品開發，以鞏固其市場地位。例如，2023年9月，百時美施貴寶以5,000萬美元從Zenas Biopharma收購雙功能單株抗體obexelimab的亞洲行銷權。此外，2022年6月，Rigel Pharmaceuticals公佈了fostamatinib在wAIHA患者中的3期臨床試驗結果，研究地點位於美國、加拿大、澳洲和西歐，結果顯示接受fostamatinib治療的患者。 。

自體免疫溶血性貧血治療市場報告亮點

  • 由於wAIHA的高盛行率和高治療率，2023年自體免疫免疫性溶血性貧血治療市場以溫性自體免疫溶血性貧血為主。
  • 由於處方率高，皮質類固醇在 2023 年佔據最大的市場佔有率。此外，皮質類固醇被認為是治療AIHA的第一線藥物。
  • 由於生物製藥研發和核准的增加，預計其他藥物類別在未來幾年將經歷最快的成長。
  • 從給藥途徑來看，由於擴大採用以患者為中心的方法以及正在研發中的有前途的口服藥物（例如利扎布替尼），口服藥物預計將成長最快。
  • 由於疾病盛行率高、市場參與者強大以及該地區良好的報銷政策等因素，北美在市場上佔據主導地位。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章自體免疫溶血性貧血治療市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 自體免疫溶血性貧血治療市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章自體免疫溶血性貧血治療市場：類型估計與趨勢分析

  • 全球自體免疫溶血性貧血治療市場：類型儀表板
  • 全球自體免疫溶血性貧血治療市場：類型變異分析
  • 全球自體免疫溶血性貧血治療市場：按類型分類的收益
  • 溫性自體免疫溶血性貧血
  • 寒冷性自體免疫溶血性貧血
  • 其他

第5章自體免疫溶血性貧血治療市場：藥物類別估計與趨勢分析

  • 全球自體免疫溶血性貧血治療市場：藥物類別儀表板
  • 全球自體免疫免疫溶血性貧血治療市場：藥物類別變異分析
  • 全球自體免疫溶血性貧血治療市場：按藥物類別分類的收益
  • 皮質類固醇
  • 免疫抑制劑
  • 其他

第6章自體免疫溶血性貧血治療市場：給藥途徑預估及趨勢分析

  • 全球自體免疫溶血性貧血治療市場：途徑儀表板
  • 全球自體免疫溶血性貧血治療市場：給藥途徑變化分析
  • 全球自體免疫溶血性貧血治療市場依給藥途徑及收益
  • 可注射的
  • 口服
  • 其他

第7章自體免疫溶血性貧血治療市場：通路估計與趨勢分析

  • 全球自體免疫溶血性貧血治療市場：通路儀表板
  • 全球自體免疫溶血性貧血治療市場：通路波動分析
  • 全球自體免疫溶血性貧血治療市場：按通路收益
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第8章自體免疫溶血性貧血治療市場：按類型、藥物類別、給藥途徑和分銷管道分類的區域估計和趨勢分析

  • 區域儀表板
  • 2018-2030年市場規模、預測趨勢分析：
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東/非洲

第9章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商情況
    • 主要經銷商及通路夥伴名單
    • 主要客戶
    • 2023年主要企業市場佔有率分析
    • F. Hoffmann-La Roche Ltd
    • Viatris Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Sanofi
    • Lupin
    • Johnson &Johnson Services, Inc.
    • Novartis AG
    • Incyte
    • Rigel Pharmaceuticals, Inc.
    • Alpine Immune Sciences.
Product Code: GVR-4-68040-290-0

Autoimmune Hemolytic Anemia Treatment Market Growth & Trends:

The global autoimmune hemolytic anemia treatment market is anticipated to reach USD 1.16 billion by 2030, growing at a CAGR of 6.5% from 2024 to 2030, according to a new report by Grand View Research, Inc. Increasing number of autoimmune hemolytic anemia (AIHA) cases worldwide, introduction of novel therapeutic drugs, increasing R&D activities, and favorable government initiatives are some of key factors driving the growth. For instance, the incidence of AIHA in France and Denmark is estimated at around 2.4 per 100,000 and 17.0 per 100,000 population, respectively.

Increasing research & activities to develop novel drugs for AIHA treatment is anticipated to drive the market expansion. Pharmaceutical companies and research institutes are actively involved in the development of novel and effective treatment options to manage AIHA. For instance, Zenas BioPharma is involved in the development of obexelimab for patients with warm autoimmune hemolytic anemia(wAIHA). The drug is in phase 3 of clinical trials and is being evaluated for efficacy and safety in patients with wAIHA. Similarly, Novartis AG is conducting clinical trials to evaluate the safety and efficacy of Ianalumab (VAY736) in patients who failed at least one line of treatment for warm autoimmune hemolytic anemia.

Moreover, the increasing involvement of government institutes and favorable initiatives undertaken by regulatory bodies to improve healthcare services to manage rare diseases are expected to increase the introduction of effective therapeutic solutions in the coming years. For instance, in December 2019, the U.S. FDA granted orphan drug designation to nipocalimab for the treatment of wAIHA and in July 2019, the U.S. FDA granted fast track designation for nipocalimab for the same indication. Such special designations for investigating candidates are expected to speed up the clinical trials and approval process.

Key players are adopting various market strategies such as acquisition and new product development to strengthen their market position. For instance, in September 2023, Bristol Myers Squibb acquired Asian regional market rights for bifunctional monoclonal antibody obexelimab from Zenas BioPharma, paying USD 50 million. Moreover, in June 2022, Rigel Pharmaceuticals, Inc. announced the results of phase 3 clinical trials of fostamatinib in patients with wAIHA, showing that patients treated with fostamatinib had a favorable durable hemoglobin response at the U.S., Canadian, Australian, and Western European trial sites.

Autoimmune Hemolytic Anemia Treatment Market Report Highlights:

  • The warm autoimmune hemolytic anemia type segment dominated the market in 2023 owing to a high prevalence of wAIHA and treatment rate.
  • The corticosteroids segment held the largest market share in 2023, owing to the high prescription rate. Moreover, corticosteroids are considered as the first line of treatment for AIHA.
  • The other drug class segment is projected to experience the fastest growth during the projected years owing to increasing R&D and approval of biological drugs.
  • In the route of administration segment, oral drugs are anticipated to grow at the fastest rate owing to the increasing adoption of patient-centric approaches and the presence of promising oral drugs such as rilzabrutinib in the pipeline.
  • North America dominated the market owing to factors such as high disease incidence, the presence of strong market players, and better reimbursement policies in the region.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Drug Class
    • 1.2.3. Route of Administration
    • 1.2.4. Distribution Channel
    • 1.2.5. Regional scope
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type and drug class outlook
    • 2.2.2. Route of administration and distribution channel outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Autoimmune Hemolytic Anemia Treatment Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing incidence of disease
      • 3.2.1.2. Increasing geriatric population
      • 3.2.1.3. Rise in R&D activities
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High cost of novel drug development for rare diseases
  • 3.3. Autoimmune Hemolytic Anemia Treatment Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's Five Forces
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Autoimmune Hemolytic Anemia Treatment Market: Type Estimates & Trend Analysis

  • 4.1. Global Autoimmune Hemolytic Anemia Treatment Market: Type Dashboard
  • 4.2. Global Autoimmune Hemolytic Anemia Treatment Market: Type Movement Analysis
  • 4.3. Global Autoimmune Hemolytic Anemia Treatment Market by Type, Revenue
  • 4.4. Warm Autoimmune Hemolytic Anemia
    • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Cold Autoimmune Hemolytic Anemia
    • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Others
    • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Autoimmune Hemolytic Anemia Treatment Market: Drug Class Estimates & Trend Analysis

  • 5.1. Global Autoimmune Hemolytic Anemia Treatment Market: Drug Class Dashboard
  • 5.2. Global Autoimmune Hemolytic Anemia Treatment Market: Drug Class Movement Analysis
  • 5.3. Global Autoimmune Hemolytic Anemia Treatment Market by Drug Class, Revenue
  • 5.4. Corticosteroids
    • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Immunosuppressive agents
    • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Others
    • 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Autoimmune Hemolytic Anemia Treatment Market: Route of Administration Estimates & Trend Analysis

  • 6.1. Global Autoimmune Hemolytic Anemia Treatment Market: Route of Administration Dashboard
  • 6.2. Global Autoimmune Hemolytic Anemia Treatment Market: Route of Administration Movement Analysis
  • 6.3. Global Autoimmune Hemolytic Anemia Treatment Market by Route of Administration, Revenue
  • 6.4. Injectable
    • 6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Oral
    • 6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Autoimmune Hemolytic Anemia Treatment Market: Distribution Channel Estimates & Trend Analysis

  • 7.1. Global Autoimmune Hemolytic Anemia Treatment Market: Distribution Channel Dashboard
  • 7.2. Global Autoimmune Hemolytic Anemia Treatment Market: Distribution Channel Movement Analysis
  • 7.3. Global Autoimmune Hemolytic Anemia Treatment Market by Distribution Channel, Revenue
  • 7.4. Hospital Pharmacy
    • 7.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Retail Pharmacy
    • 7.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Online Pharmacy
    • 7.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Autoimmune Hemolytic Anemia Treatment Market: Regional Estimates & Trend Analysis by Type, Drug Class, Route of Administration, and Distribution Channel

  • 8.1. Regional Dashboard
  • 8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 8.3. North America
    • 8.3.1. U.S.
      • 8.3.1.1. Key country dynamics
      • 8.3.1.2. Regulatory framework/ reimbursement structure
      • 8.3.1.3. Competitive scenario
      • 8.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.3.2. Canada
      • 8.3.2.1. Key country dynamics
      • 8.3.2.2. Regulatory framework/ reimbursement structure
      • 8.3.2.3. Competitive scenario
      • 8.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4. Europe
    • 8.4.1. UK
      • 8.4.1.1. Key country dynamics
      • 8.4.1.2. Regulatory framework/ reimbursement structure
      • 8.4.1.3. Competitive scenario
      • 8.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.2. Germany
      • 8.4.2.1. Key country dynamics
      • 8.4.2.2. Regulatory framework/ reimbursement structure
      • 8.4.2.3. Competitive scenario
      • 8.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.3. France
      • 8.4.3.1. Key country dynamics
      • 8.4.3.2. Regulatory framework/ reimbursement structure
      • 8.4.3.3. Competitive scenario
      • 8.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.4. Italy
      • 8.4.4.1. Key country dynamics
      • 8.4.4.2. Regulatory framework/ reimbursement structure
      • 8.4.4.3. Competitive scenario
      • 8.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.5. Spain
      • 8.4.5.1. Key country dynamics
      • 8.4.5.2. Regulatory framework/ reimbursement structure
      • 8.4.5.3. Competitive scenario
      • 8.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.6. Norway
      • 8.4.6.1. Key country dynamics
      • 8.4.6.2. Regulatory framework/ reimbursement structure
      • 8.4.6.3. Competitive scenario
      • 8.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.7. Sweden
      • 8.4.7.1. Key country dynamics
      • 8.4.7.2. Regulatory framework/ reimbursement structure
      • 8.4.7.3. Competitive scenario
      • 8.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.8. Denmark
      • 8.4.8.1. Key country dynamics
      • 8.4.8.2. Regulatory framework/ reimbursement structure
      • 8.4.8.3. Competitive scenario
      • 8.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5. Asia Pacific
    • 8.5.1. Japan
      • 8.5.1.1. Key country dynamics
      • 8.5.1.2. Regulatory framework/ reimbursement structure
      • 8.5.1.3. Competitive scenario
      • 8.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.2. China
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework/ reimbursement structure
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.3. India
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory framework/ reimbursement structure
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.4. Australia
      • 8.5.4.1. Key country dynamics
      • 8.5.4.2. Regulatory framework/ reimbursement structure
      • 8.5.4.3. Competitive scenario
      • 8.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.5. South Korea
      • 8.5.5.1. Key country dynamics
      • 8.5.5.2. Regulatory framework/ reimbursement structure
      • 8.5.5.3. Competitive scenario
      • 8.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.6. Thailand
      • 8.5.6.1. Key country dynamics
      • 8.5.6.2. Regulatory framework/ reimbursement structure
      • 8.5.6.3. Competitive scenario
      • 8.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6. Latin America
    • 8.6.1. Brazil
      • 8.6.1.1. Key country dynamics
      • 8.6.1.2. Regulatory framework/ reimbursement structure
      • 8.6.1.3. Competitive scenario
      • 8.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.2. Mexico
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework/ reimbursement structure
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.3. Argentina
      • 8.6.3.1. Key country dynamics
      • 8.6.3.2. Regulatory framework/ reimbursement structure
      • 8.6.3.3. Competitive scenario
      • 8.6.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7. MEA
    • 8.7.1. South Africa
      • 8.7.1.1. Key country dynamics
      • 8.7.1.2. Regulatory framework/ reimbursement structure
      • 8.7.1.3. Competitive scenario
      • 8.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.2. Saudi Arabia
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework/ reimbursement structure
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.3. UAE
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework/ reimbursement structure
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.4. Kuwait
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework/ reimbursement structure
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
  • 9.3. Vendor Landscape
    • 9.3.1. List of key distributors and channel partners
    • 9.3.2. Key customers
    • 9.3.3. Key company market share analysis, 2023
    • 9.3.4. F. Hoffmann-La Roche Ltd
      • 9.3.4.1. Company overview
      • 9.3.4.2. Financial performance
      • 9.3.4.3. Product benchmarking
      • 9.3.4.4. Strategic initiatives
    • 9.3.5. Viatris Inc.
      • 9.3.5.1. Company overview
      • 9.3.5.2. Financial performance
      • 9.3.5.3. Product benchmarking
      • 9.3.5.4. Strategic initiatives
    • 9.3.6. Teva Pharmaceutical Industries Ltd.
      • 9.3.6.1. Company overview
      • 9.3.6.2. Financial performance
      • 9.3.6.3. Product benchmarking
      • 9.3.6.4. Strategic initiatives
    • 9.3.7. Sanofi
      • 9.3.7.1. Company overview
      • 9.3.7.2. Financial performance
      • 9.3.7.3. Product benchmarking
      • 9.3.7.4. Strategic initiatives
    • 9.3.8. Lupin
      • 9.3.8.1. Company overview
      • 9.3.8.2. Financial performance
      • 9.3.8.3. Product benchmarking
      • 9.3.8.4. Strategic initiatives
    • 9.3.9. Johnson & Johnson Services, Inc.
      • 9.3.9.1. Company overview
      • 9.3.9.2. Financial performance
      • 9.3.9.3. Product benchmarking
      • 9.3.9.4. Strategic initiatives
    • 9.3.10. Novartis AG
      • 9.3.10.1. Company overview
      • 9.3.10.2. Financial performance
      • 9.3.10.3. Product benchmarking
      • 9.3.10.4. Strategic initiatives
    • 9.3.11. Incyte
      • 9.3.11.1. Company overview
      • 9.3.11.2. Financial performance
      • 9.3.11.3. Product benchmarking
      • 9.3.11.4. Strategic initiatives
    • 9.3.12. Rigel Pharmaceuticals, Inc.
      • 9.3.12.1. Company overview
      • 9.3.12.2. Financial performance
      • 9.3.12.3. Product benchmarking
      • 9.3.12.4. Strategic initiatives
    • 9.3.13. Alpine Immune Sciences.
      • 9.3.13.1. Company overview
      • 9.3.13.2. Financial performance
      • 9.3.13.3. Product benchmarking
      • 9.3.13.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 North America autoimmune hemolytic anemia treatment market, by country, 2018 - 2030 (USD Million)
  • Table 3 North America autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
  • Table 4 North America autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 5 North America autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 6 North America autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 7 U.S. autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
  • Table 8 U.S. autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 9 U.S. autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 10 U.S. autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 11 Canada autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
  • Table 12 Canada autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 13 Canada autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 14 Canada autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 15 Europe autoimmune hemolytic anemia treatment market, by country, 2018 - 2030 (USD Million)
  • Table 16 Europe autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
  • Table 17 Europe autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 18 Europe autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 19 Europe autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 20 Germany autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
  • Table 21 Germany autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 22 Germany autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 23 Germany autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 24 UK autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
  • Table 25 UK autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 26 UK autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 27 UK autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 28 France autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
  • Table 29 France autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 30 France autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 31 France autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 32 Italy autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
  • Table 33 Italy autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 34 Italy autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 35 Italy autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 36 Spain autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
  • Table 37 Spain autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 38 Spain autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 39 Spain autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 40 Denmark autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
  • Table 41 Denmark autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 42 Denmark autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 43 Denmark autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 44 Sweden autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
  • Table 45 Sweden autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 46 Sweden autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 47 Sweden autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 48 Norway autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
  • Table 49 Norway autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 50 Norway autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 51 Norway autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 52 Asia Pacific autoimmune hemolytic anemia treatment market, by region, 2018 - 2030 (USD Million)
  • Table 53 Asia Pacific autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
  • Table 54 Asia Pacific autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 55 Aisa Pacific autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 56 Aisa Pacific autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 57 China autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
  • Table 58 China autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 59 China autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 60 China autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 61 Japan autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
  • Table 62 Japan autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 63 Japan autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 64 Japan autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 65 India autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
  • Table 66 India autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 67 India autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 68 India autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 69 South Korea autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
  • Table 70 South Korea autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 71 South Korea autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 72 South Korea autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 73 Australia autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
  • Table 74 Australia autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 75 Australia autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 76 Australia autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 77 Thailand autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
  • Table 78 Thailand autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 79 Thailand autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 80 Thailand autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 81 Latin America autoimmune hemolytic anemia treatment market, by region, 2018 - 2030 (USD Million)
  • Table 82 Latin America autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
  • Table 83 Latin America autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 84 Latin America autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 85 Latin America autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 86 Brazil autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
  • Table 87 Brazil autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 88 Brazil autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 89 Brazil autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 90 Mexico autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
  • Table 91 Mexico autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 92 Mexico autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 93 Mexico autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 94 Argentina autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
  • Table 95 Argentina autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 96 Argentina autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 97 Argentina autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 98 MEA autoimmune hemolytic anemia treatment market, by region, 2018 - 2030 (USD Million)
  • Table 99 MEA autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
  • Table 100 MEA autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 101 MEA autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 102 MEA autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 103 South Africa autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
  • Table 104 South Africa autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 105 South Africa autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 106 South Africa autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 107 Saudi Arabia autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
  • Table 108 Saudi Arabia autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 109 Saudi Arabia autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 110 Saudi Arabia autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 111 UAE autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
  • Table 112 UAE autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 113 UAE autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 114 UAE autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 115 Kuwait autoimmune hemolytic anemia treatment market, by type, 2018 - 2030 (USD Million)
  • Table 116 Kuwait autoimmune hemolytic anemia treatment market, by drug class, 2018 - 2030 (USD Million)
  • Table 117 Kuwait autoimmune hemolytic anemia treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 118 Kuwait autoimmune hemolytic anemia treatment market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Autoimmune hemolytic anemia treatment market: market outlook
  • Fig. 14 Autoimmune hemolytic anemia treatment competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Autoimmune hemolytic anemia treatment market driver impact
  • Fig. 18 Autoimmune hemolytic anemia treatment market restraint impact
  • Fig. 19 Autoimmune hemolytic anemia treatment market: Type movement analysis
  • Fig. 20 Autoimmune hemolytic anemia treatment market: Type outlook and key takeaways
  • Fig. 21 Warm autoimmune hemolytic anemia market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Cold autoimmune hemolytic anemia market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Autoimmune hemolytic anemia treatment market: Drug class movement analysis
  • Fig. 25 Autoimmune hemolytic anemia treatment market: Drug class outlook and key takeaways
  • Fig. 26 Corticosteroids market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Immunosuppressive agents market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Autoimmune hemolytic anemia treatment market: Route of administration movement analysis
  • Fig. 30 Autoimmune hemolytic anemia treatment market: Route of administration outlook and key takeaways
  • Fig. 31 Oral market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Injectable market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 Autoimmune hemolytic anemia treatment market: Distribution channel movement analysis
  • Fig. 35 Autoimmune hemolytic anemia treatment market: Distribution channel outlook and key takeaways
  • Fig. 36 Hospital pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Retail pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Online pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 39 Global Autoimmune hemolytic anemia treatment market: Regional movement analysis
  • Fig. 40 Global Autoimmune hemolytic anemia treatment market: Regional outlook and key takeaways
  • Fig. 41 Global Autoimmune hemolytic anemia treatment market share and leading players
  • Fig. 42 North America, by country
  • Fig. 43 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 U.S. key country dynamics
  • Fig. 45 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Canada key country dynamics
  • Fig. 47 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 UK key country dynamics
  • Fig. 50 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Germany key country dynamics
  • Fig. 52 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 France key country dynamics
  • Fig. 54 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Italy key country dynamics
  • Fig. 56 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Spain key country dynamics
  • Fig. 58 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Denmark key country dynamics
  • Fig. 60 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Sweden key country dynamics
  • Fig. 62 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Norway key country dynamics
  • Fig. 64 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 China key country dynamics
  • Fig. 67 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Japan key country dynamics
  • Fig. 69 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 India key country dynamics
  • Fig. 71 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 Thailand key country dynamics
  • Fig. 73 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 South Korea key country dynamics
  • Fig. 75 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Australia key country dynamics
  • Fig. 77 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 Brazil key country dynamics
  • Fig. 80 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Mexico key country dynamics
  • Fig. 82 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 Argentina key country dynamics
  • Fig. 84 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 85 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 South Africa key country dynamics
  • Fig. 87 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 Saudi Arabia key country dynamics
  • Fig. 89 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 90 UAE key country dynamics
  • Fig. 91 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 92 Kuwait key country dynamics
  • Fig. 93 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 94 Market share of key market players- 2023